Clinical Trial Update by Immune Oncology Research Institute

Immune Oncology Research Institute shared on LinkedIn:

“Clinical Trial Update!

Update on the ‘Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone. Can This Modality Improve the Antiemetic Effect?’ trial.

The trial, conducted at the Pediatric Cancer and Blood Disorders Center of Armenia by the Immune Oncology Research Institute, has enrolled 27 patients and completed over 100 chemotherapy cycles after a year of its launch.

Despite numerous challenges, the trial has been made possible by a dedicated and exceptional team. It seeks to identify more effective methods for preventing chemotherapy-induced nausea and vomiting.

• The investigators of the trial

Julieta Hoveyan MD and Ruzanna Papyan MD, anticipate concluding the trial and publishing the initial data by June 2025.

For more information.”

Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone

Source: IMMONC/LinkedIn